Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

Beth Israel Lahey Health

Status: Terminated

Conditions: IBS

Treatments: Drug: VSL#3

Study type: Interventional

Funder types: Other

Identifiers

NCT00179582

2004P000001

VSL1

Details and patient eligibility

About

To evaluate the effects of VSL#3 on symptoms associated with diarrhea predominant IBS

Full description

The study will evaluate 2 doses of VSL#3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms.

Enrollment: 180 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• IBS diarrhea

Exclusion criteria

• < 18 years of age
• Pregnancy/breast feeding
• concomitant medications to reduce bowel function

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind